A study published in the European Heart Journal on Feb. 18 suggests healthcare expenditures in Europe would skyrocket if local systems adopted experts’ latest guidelines for cholesterol-lowering treatment.
Many Americans who can’t afford prescription insulin for their diabetes are turning to unregulated, illegal markets for discounted products, researchers reported in JAMA Internal Medicine this month.
Research out of the Yale School of Public Health in New Haven, Conn., has revealed a relationship between rosiglitazone, a type 2 diabetes drug, and heart disease.
People who begin taking antihypertensive drugs or lipid-lowerers like statins are more likely than non-initiators to become obese and physically inactive, a JAHA study has found—but they’re also more likely to quit smoking and keep their alcohol intake in check.
The Mediterranean diet has been eclipsed as the U.S. News & World Report’s best-ranked heart-healthy diet for the first time in a decade, nudged out of the top spot by the popular Ornish diet.
A two-year collaboration between the North Carolina chapter of the American College of Cardiology and North Carolina Association of Free and Charitable Clinics was successful in providing thousands of underserved heart patients with free lipid-lowering therapy and clopidogrel.
More than 15% of adults in all U.S. states and territories were physically inactive between 2015 and 2018, according to recent data from the CDC, with estimates ranging from 17.3% to 47.7% between regions.
The FDA has approved Novo Nordisk’s Ozempic—once-weekly semaglutide—for an expanded indication of CV risk reduction in people with type 2 diabetes and established heart disease.
A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.
